Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals.
Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $421,112 and 6, calls, for a total amount of $246,689.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $650.0 to $820.0 for Regeneron Pharmaceuticals during the past quarter.
Volume & Open Interest Development
In today's trading context, the average open interest for options of Regeneron Pharmaceuticals stands at 66.2, with a total volume reaching 277.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Regeneron Pharmaceuticals, situated within the strike price corridor from $650.0 to $820.0, throughout the last 30 days.
Regeneron Pharmaceuticals Option Activity Analysis: Last 30 Days
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | PUT | TRADE | BULLISH | 09/19/25 | $46.5 | $39.8 | $41.0 | $650.00 | $184.5K | 99 | 45 |
| REGN | PUT | TRADE | BULLISH | 08/15/25 | $66.2 | $58.0 | $61.28 | $710.00 | $122.5K | 30 | 20 |
| REGN | PUT | SWEEP | BULLISH | 08/15/25 | $61.6 | $53.0 | $55.58 | $700.00 | $83.3K | 10 | 15 |
| REGN | CALL | SWEEP | BULLISH | 01/17/25 | $39.2 | $36.9 | $39.2 | $700.00 | $74.2K | 143 | 19 |
| REGN | CALL | SWEEP | BEARISH | 01/24/25 | $11.9 | $10.2 | $11.0 | $760.00 | $49.5K | 2 | 61 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Regeneron Pharmaceuticals's Current Market Status
- Currently trading with a volume of 347,017, the REGN's price is up by 0.23%, now at $719.79.
- RSI readings suggest the stock is currently may be approaching oversold.
- Anticipated earnings release is in 25 days.
Expert Opinions on Regeneron Pharmaceuticals
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $365.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from Canaccord Genuity downgraded its action to Hold with a price target of $165. * Reflecting concerns, an analyst from B of A Securities lowers its rating to Underperform with a new price target of $565.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
